Pfizer: clinical trial deal with SpringWorks
(CercleFinance.com) - Pfizer has entered into a deal with US biotech firm SpringWorks to evaluate a combination of two of their drugs in patients with relapsed or refractory multiple myeloma.
The clinical trial collaboration will assess SpringWorks' investigational drug nirogacestat with Pfizer's antibody PF‐06863135, which recently showed promising monotherapy clinical data, the companies said.
Under the terms of the agreement, Pfizer will sponsor and conduct a Phase 1b/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination, assuming all costs associated with the trial.
Pfizer and SpringWorks also plan to form a joint development committee to manage the clinical study, which is expected to start in the first half of 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The clinical trial collaboration will assess SpringWorks' investigational drug nirogacestat with Pfizer's antibody PF‐06863135, which recently showed promising monotherapy clinical data, the companies said.
Under the terms of the agreement, Pfizer will sponsor and conduct a Phase 1b/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination, assuming all costs associated with the trial.
Pfizer and SpringWorks also plan to form a joint development committee to manage the clinical study, which is expected to start in the first half of 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.